HopeStage
Back to all studies
CompletedNCT04116528

Ketamine and Buprenorphine for Suicidal Thoughts in Depression

About this titleRead the official source — NCT04116528
Medication studyAges 18–70United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations
StanfordSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 1, 2020
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Stanford University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 70 Years
Official registry ID
NCT04116528
Official title
Show the full official title

Opiate Suicide Study in Patients With Major Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Stanford

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Stanford University, a university.

Did this study involve medication?

Yes. The study involved medication, including Buprenorphine and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies